Get the Stockscreener App
27.75
0.47%
0.13
After Hours:
27.70
-0.05
-0.18%
Apellis Pharmaceuticals Inc stock is traded at $27.75, with a volume of 3.88M.
It is up +0.47% in the last 24 hours and up +43.41% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$27.62
Open:
$27.82
24h Volume:
3.88M
Relative Volume:
1.58
Market Cap:
$3.50B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-13.67
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
+13.87%
1M Performance:
+43.41%
6M Performance:
+1.28%
1Y Performance:
-26.24%
1-Day Range:
$27.63
$28.87
1-Week Range:
$23.75
$28.87
52-Week Range:
$16.10
$41.94
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
27.75 | 3.49B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Apellis phase 3 Empaveli data demonstrates sustained proteinuria reduction - MSN
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli’s New Approval (APLS) - Seeking Alpha
Signal strength of Apellis Pharmaceuticals Inc. stock in tech scannersJuly 2025 Summary & Daily Stock Momentum Reports - Newser
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN
Watch for Trend Continuation in Apellis Pharmaceuticals Inc. Next Week2025 Major Catalysts & Risk Controlled Swing Trade Alerts - beatles.ru
Apellis Pharmaceuticals (APLS) Surges 10.27% on FDA Approval Momentum and Strategic Deals - AInvest
FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals’ Stock Higher for the Week - Insider Monkey
Apellis Pharmaceuticals' Stock Surges 27.70% This Week Following FDA Approval, Q2 2025 Financial Results, and Capped Royalty Purchase Agreements - AInvest
Published on: 2025-08-12 03:12:35 - beatles.ru
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $20 to $57 - 富途牛牛
11 Best Short-Term Stocks to Invest in - Insider Monkey
Apellis wins FDA label expansion for Empaveli in rare kidney disorders - MSN
Fierce Biotech Layoff Tracker 2025: Tune, Bicycle let go of 25% of staff - Fierce Biotech
Apellis Pharmaceuticals' Empaveli Faces Market Challenges and Physician Preferences - AInvest
Hold Rating for Apellis Pharmaceuticals’ Empaveli Amid Market Challenges and Physician Preferences - TipRanks
Apellis Pharmaceuticals (APLS) Sees Target Price Raised by Citig - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2025 Earnings Call Transcript - Insider Monkey
Apellis Pharmaceuticals’ Earnings Call: A Balanced Outlook - TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS) and Akero Therapeutics (AKRO) - The Globe and Mail
Published on: 2025-08-04 22:37:11 - beatles.ru
Why Apellis Pharmaceuticals Shares Are Gaining Attention - TipRanks
Apellis Pharmaceuticals Inc. Stock Analysis and ForecastInvest smarter with actionable stock recommendations - Jammu Links News
Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug - MSN
Apellis’ EMPAVELI Approved by FDA for Rare Kidney Diseases - MSN
When is Apellis Pharmaceuticals Inc. stock expected to show significant growthBuild a portfolio with strong long-term growth - Jammu Links News
How many analysts rate Apellis Pharmaceuticals Inc. as a “Buy”Exceptional profit potential - Jammu Links News
What makes Apellis Pharmaceuticals Inc. stock price move sharplyDiscover undervalued stocks ready to soar - Jammu Links News
Is Apellis Pharmaceuticals Inc. a growth stock or a value stockFree Stock Movement Tracking - Jammu Links News
How strong is Apellis Pharmaceuticals Inc. company’s balance sheetBuild wealth steadily with proven investment techniques - Jammu Links News
How volatile is Apellis Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough growth with proven strategies - Jammu Links News
What analysts say about Apellis Pharmaceuticals Inc. stockConsistent triple-digit returns - Jammu Links News
What catalysts could drive Apellis Pharmaceuticals Inc. stock higher in 2025High-octane investment gains - Jammu Links News
What drives Apellis Pharmaceuticals Inc. stock priceCapitalize on market trends before they peak - Jammu Links News
What institutional investors are buying Apellis Pharmaceuticals Inc. stockFree Stock Movement Tracking - Jammu Links News
Why is Apellis Pharmaceuticals Inc. stock attracting strong analyst attentionUnlock exclusive stock market forecasts - Jammu Links News
How does Apellis Pharmaceuticals Inc. generate profit in a changing economyUnlock powerful portfolio optimization tools - Jammu Links News
What are Apellis Pharmaceuticals Inc. company’s key revenue driversBuild a portfolio that stands the test of time - Jammu Links News
Apellis Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Apellis Pharmaceuticals: Navigating Q2 Earnings and Building a Complement-Driven Ophthalmology Powerhouse - AInvest
What are the latest earnings results for Apellis Pharmaceuticals Inc.Free Stock Target Finder For Fast Growth - jammulinksnews.com
Apellis Pharmaceuticals (APLS) Stock Forecast and Price Target 2025 - MarketBeat
Apellis Pharmaceuticals: The Picture Becomes Clearer (NASDAQ:APLS) - Seeking Alpha
Apellis Pharmaceuticals Surges 17.6% on Higher Price Target from Scotiabank - AInvest
Apellis (APLS) Price Target Raised as Market Stabilizes - GuruFocus
RBC Capital Raises Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News - GuruFocus
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $19 to $57 - 富途牛牛
Raymond James Adjusts Price Target for Apellis (APLS) After Q2 E - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Surges 25% Yet Its Low P/S Is No Reason For Excitement - 富途牛牛
APLS: Cantor Fitzgerald Raises Price Target for Apellis Pharmace - GuruFocus
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say - MSN
Analyst Raymond James Lowers Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News - GuruFocus
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Apellis Pharmaceuticals Inc Stock (APLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Francois Cedric | Chief Executive Officer |
Jul 17 '25 |
Sale |
20.21 |
19,725 |
398,735 |
331,605 |
| Watson David O. | General Counsel |
Jul 16 '25 |
Sale |
19.55 |
5,000 |
97,750 |
128,730 |
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):